TITLE

Review: Cholinesterase inhibitors may be effective in Alzheimer disease: COMMENTARY

AUTHOR(S)
Luckmann, Roger
PUB. DATE
January 2006
SOURCE
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on a clinical study according to which cholinesterase inhibitors may be effective in treating Alzheimer disease (AD). The current consensus on cholinesterase inhibitors in the treatment of AD is that they probably have a small positive effect on cognitive function, and possibly behavior, in some patients, but the clinical significance of the effect may be marginal. They describe most flaws accurately but sometimes mischaracterize them or overstate their significance. The authors of the study, however, correctly highlight the potentially serious bias that could result from the absence of final outcome measures on most patients who are withdrawn. Clinicians still must struggle with how to identify responders to cholinesterase inhibitors, how long to treat, and whether a trial of medication is cost-effective.
ACCESSION #
19516008

 

Related Articles

  • Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer's Disease. Schachter, A.S.; Davis, K.L. // CNS Drugs;1999, Vol. 11 Issue 4, p281 

    The cholinesterase inhibitors are the only available scientifically proven symptomatic treatments for dementia of the Alzheimer's type. The guidelines we present summarise the current updated knowledge on the available drugs, including tacrine, donepezil, rivastigmine, metrifonate and...

  • Defining Treatment Response to Donepezil in AlzheimerÂ’s Disease: Responder Analysis of Patient-Level Data from Randomized, Placebo-Controlled Studies. Burns, Alistair; Yeates, Andrew; Akintade, Latif; del Valle, Megan; Zhang, Richard Y.; Schwam, Elias M.; Perdomo, Carlos A. // Drugs & Aging;2008, Vol. 25 Issue 8, p707 

    BACKGROUND: Defining treatment success in progressive diseases, such as Alzheimer’s disease (AD), can be challenging. OBJECTIVE: To explore the impact of employing different criteria to define a treatment ‘responder’ using analyses of patient-level data from randomized,...

  • galantamine.  // Royal Society of Medicine: Medicines;2002, p261 

    The article presents information on galantamine. The drug is an anticholinesterase recently introduced for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities...

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...

  • Cholinesterase Inhibitors in Alzheimer's Disease: Are they Worth the Cost? Whitehouse, P.J. // CNS Drugs;1999, Vol. 11 Issue 3, p167 

    Several cholinesterase inhibitors have demonstrated their ability to improve cognition in Alzheimer's disease. This paper reviews issues important to determining whether cholinesterase inhibitors are worth their cost. Establishing therapeutic goals in Alzheimer's disease and assessing initial...

  • Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. Onder, Graziano; Zanetti, Orazio; Giacobini, Ezio; Frisoni, Giovanni B.; Bartorelli, Luisa; Carbone, Gabriele; Lambertucci, Paola; Silveri, Maria Caterina; Bernabei, Roberto // British Journal of Psychiatry;Nov2005, Vol. 187, p450 

    Background Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease. Aims To perform such an evaluation. Method We randomly assigned 79 of 156 patients treated with donepezil to receive a reality orientation programme....

  • Cholinesterase inhibitors and cardiac arrhythmias.  // WHO Drug Information;2004, Vol. 18 Issue 4, p273 

    Focuses on the usage of cholinesterase inhibitors for the treatment of Alzheimer's disease. Presentation of cardiac arrhythmias and other effects with cholinesterase inhibitors; Awareness of the prescribers of the potential for cardiac arrhythmias, particularly bradycardia with cholinesterase...

  • donepezil.  // Royal Society of Medicine: Medicines;2002, p214 

    This article presents information on the anticholinesterase donepezil used for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities have identified those...

  • EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. Kogan, E. A.; Korczyn, A. D.; Virchovsky, R. G.; Klimovizky, S. Sh.; Treves, T. A.; Neufeld, M. Y. // Journal of Neural Transmission;Oct2001, Vol. 108 Issue 10, p1167 

    Summary. In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics